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Abstract  
IgG4-related disease (IgG4-RD) has rarely been reported as presenting with Adult Onset Asthma with 
Periorbital Xanthogranulomatosis (AAPOX). There is emerging evidence that serum IgG2 elevation 
may predate IgG4 elevation in both serum and tissues in patients with IgG4-RD. We present here the 
case of a 57 year old patient who developed AAPOX with no histological or serum evidence of IgG4 
elevation, but an isolated raised serum IgG2 at onset. We give evidence that over time her clinical 
picture became more consistent with IgG4-RD, and that immunosuppression with Methotrexate may 
have attenuated the serological evolution of disease. We believe that further work is required to 
elucidate the true natural history of serological and histological progression in IgG4-RD as, at least in 
a sub-set of patients, isolated serum IgG2 elevation at presentation appears to be a precursor to 
disease. 
 
Key message 
Elevation of serum IgG2 may be a precursor to classical IgG4-related disease 
 
 
 
 
 
 
 
 
Case report 
Dear Sir, 
A 57 year old female baker presented with a 7 year history of systemic illness comprising cervical 
lymphadenopathy, sinusitis, smell and taste disturbance, adult-onset asthma and bilateral eyelid 
swellings.  Biopsy of the eyelids confirmed xanthogranulomatous inflammation with Touton giant 
cells without evidence of elevated IgG4 plasma cells [Fig 1]. The patient was known to be a 
haemochromatosis carrier, but had no other past medical history.  Treatment was with 
beclometasone and salbutamol inhalers only. 
Baseline blood tests showed elevation of serum IgG2, normal IgG4 and a peripheral eosinophilia (see 
below) Erythrocyte sedimentation rate and C-reactive protein were within normal limits and have 
remained so.  
An initial diagnosis of adult onset asthma with periorbital xanthogranulomatosis (AAPOX)1,2 was 
made. Haematological review showed no evidence of underlying haematological malignancy; CT of 
the chest, abdomen and pelvis showed bilateral isolated 13mm axillary lymph nodes, felt to be 
reactive . X-rays of the long bones showed no changes consistent with Erdheim Chester disease 
(known to be associated with AAPOX) 1,2 . 
 Empirically the patient was treated with a short course of oral prednisolone, 30mg once daily for 14 
days, to assess reversibility of symptoms. Wheeziness, smell / taste disturbance and orbital swelling 
all improved. Based on the available literature1,2,  Methotrexate 15mg once weekly was commenced 
to suppress the systemic inflammation. 
Clinically the Methotrexate was well tolerated but there was no definitive improvement in the 
orbital swelling or severity of asthma. Serologically, the peripheral eosinophilia and IgG2 levels 
reduced whilst on Methotrexate, but there was no response in the persistently raised IgE. Serum 
IgG4 remained normal immediately prior to commencing Methotrexate [see below].   
After 15 months on Methotrexate, given the uncertainty about clinical effectiveness, the 
Methotrexate was reduced with a view to stopping.  At 7.5mg weekly, the patient felt that her upper 
and lower respiratory symptoms had worsened, and she had also developed episodes of increased 
orbital swelling. Methotrexate was not increased however as she was retiring from work, where her 
occupational exposure to fine, gluten free flour had been suspected as a possible trigger to her 
original illness (symptoms began shortly after this occupational exposure 9 years earlier). Retirement 
did not bring a resolution of her symptoms, but she started to experience general malaise associated 
with Methotrexate and stopped this herself 29 months after commencing.  
Off Methotrexate her systemic symptoms were a little worse ʹ increased nasal symptoms 
predominantly; wheeziness stable on inhaled therapy [Fluticasone/ Vilanterol combination inhaler]. 
The orbital swelling continued to be variable as it had been throughout the course of the illness. 
Serological markers however were all increased, with recurrence of peripheral eosinophilia and 
elevated serum IgG2 as at presentation. More interestingly, 6 months earlier, whilst still on low dose 
oral Methotrexate, the serum IgG4 had been measured as high for the first time, and after 3 months 
off Methotrexate the serum IgG4 level had reached nearly 9 times the upper limit of normal [see 
below]. The patient remains clinically well off all systemic treatment, but under continued 
observation. 
The serological progression over time is summarised as follows: March 2013 (pre-treatment) IgG2 
7.24g/L (1.2-6.6), IgG4 0.38g/L (0-1.3), eosinophils 1.3x109 /L (0.04-0.5), February 2014 pre-
methotrexate but after steroids 6.27, 0.4 and 1.39 respectively, with IgE 231 KU/L (0-81), June 2016 
whilst on Methotrexate 6.43, 5.26, 0.55 respectively, with IgE 303. December 2016, off all treatment 
for 3 months, all elevated at 11.7, 11.5, 1.07 respectively, IgE 420. 
Although rare, IgG4-RD presenting as AAPOX has been reported previously3 . Serological IgG2 
elevation in isolation, as a precursor for IgG4-RD, has also recently be reported in a large case series 
of patients with orbital disease by ourselves, in collaboration with colleagues in Singapore4 .  What 
remains uncertain is the timeline. Is IgG2 elevated in all patients with IgG4-RD as a precursor to 
disease or just a sub-set? Does the IgG4 rise inexorably over time, in this case months to years, or 
does immunosuppressive treatment attenuate this? Did the treatment with Methotrexate here 
suppress and delay the emergence of elevated serum IgG4 or would the curve of serum IgG4 have 
progressed exponentially regardless? 
Either way, at presentation this patient had neither serological nor histological evidence of IgG4-RD. 
Over time, a more classical serological pattern consistent with IgG4-RD has emerged, in a clinically 
consistent context. More work is required to ascertain the natural history of this condition, in 
particular the timeline of relevant serological markers in all patients with IgG4-RD. What this case 
does illustrate, however, is that in patients with a clinical picture suggestive of IgG4-RD, isolated 
elevation of serum IgG2 at presentation can be relevant and a precursor to the full clinical 
syndrome, at least in a sub-set of patients.   
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Figure 1 legend 
Haematoxylin & Eosin stained tissue section showing numerous foamy histiocytes (black arrow) 
with some other mixed inflammatory cells comprising lymphocytes and plasma cells and fibrosis. 
Touton giant cells were scattered around the lesion (inset top right).  
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